Explore the vast range of titles available.

The population prevalence of multimorbidity (the existence of at least 2 or more long-term conditions [LTCs] in an individual) is increasing among young adults, particularly in minority ethnic groups and individuals living in socioeconomically deprived areas. In this study, we applied a data-driven approach to identify clusters of individuals who had an early onset multimorbidity in an ethnically and socioeconomically diverse population. We identified associations between clusters and a range of health outcomes. Using linked primary and secondary care data from the Clinical Practice Research Datalink GOLD (CPRD GOLD), we conducted a cross-sectional study of 837,869 individuals with early onset multimorbidity (aged between 16 and 39 years old when the second LTC was recorded) registered with an English general practice between 2010 and 2020. The study population included 777,906 people of White ethnicity (93%), 33,915 people of South Asian ethnicity (4%), and 26,048 people of Black African/Caribbean ethnicity (3%). A total of 204 LTCs were considered. Latent class analysis stratified by ethnicity identified 4 clusters of multimorbidity in White groups and 3 clusters in South Asian and Black groups. We found that early onset multimorbidity was more common among South Asian (59%, 33,915) and Black (56% 26,048) groups compared to the White population (42%, 777,906). Latent class analysis revealed physical and mental health conditions that were common across all ethnic groups (i.e., hypertension, depression, and painful conditions). However, each ethnic group also presented exclusive LTCs and different sociodemographic profiles: In White groups, the cluster with the highest rates/odds of the outcomes was predominantly male (54%, 44,150) and more socioeconomically deprived than the cluster with the lowest rates/odds of the outcomes. On the other hand, South Asian and Black groups were more socioeconomically deprived than White groups, with a consistent deprivation gradient across all multimorbidity clusters. At the end of the study, 4% (34,922) of the White early onset multimorbidity population had died compared to 2% of the South Asian and Black early onset multimorbidity populations (535 and 570, respectively); however, the latter groups died younger and lost more years of life. The 3 ethnic groups each displayed a cluster of individuals with increased rates of primary care consultations, hospitalisations, long-term prescribing, and odds of mortality. Study limitations include the exclusion of individuals with missing ethnicity information, the age of diagnosis not reflecting the actual age of onset, and the exclusion of people from Mixed, Chinese, and other ethnic groups due to insufficient power to investigate associations between multimorbidity and health-related outcomes in these groups. These findings emphasise the need to identify, prevent, and manage multimorbidity early in the life course. Our work provides additional insights into the excess burden of early onset multimorbidity in those from socioeconomically deprived and diverse groups who are disproportionately and more severely affected by multimorbidity and highlights the need to ensure healthcare improvements are equitable.

Background Despite increased understanding of psoriasis pathogenesis, molecular classification of clinical phenotypes and disease severity is poorly defined. Knowledge gaps include whether molecular endotypes of psoriasis underlie distinct clinical phenotypes and the positive and negative molecular regulators of disease severity across tissue compartments. Methods We performed comprehensive RNA sequencing of skin and blood (n = 718) from prospectively-recruited, deeply-phenotyped discovery and replication cohorts of 146 subjects with moderate-to-severe chronic plaque psoriasis initiating TNF-inhibitor (adalimumab) or IL-12/23-inhibitor (ustekinumab) therapy. Results Here we show, using two complementary dimensionality reduction methods, that co-expressed gene modules and factors within skin and blood are significantly associated with psoriasis phenotypes and disease severity. We identify a 14-gene signature negatively associated with BMI in nonlesional skin and with disease severity in lesional skin. Genotype integration reveals that HLA-DQA1*01 and HLA-DRB1*15 genotypes are positively associated with baseline psoriasis severity. Using explainable machine learning models, we define two disease severity-associated gene modules in lesional skin - one positive, one negatively-associated - and a 9-gene signature in lesional skin predictive of disease severity. Disease severity signatures in blood are only seen following adalimumab exposure, suggesting greater systemic impact of adalimumab compared to ustekinumab, in line with its side effect profile. In contrast, a gene signature in blood linked to HLA-C*06:02 status is independent of disease severity or drug. Conclusions These findings delineate gene-environmental and genetic effects on the psoriasis transcriptome linked to disease severity. Plain language summary Psoriasis is a common and debilitating skin disease, linked to other inflammatory conditions. A lot is known about what causes psoriasis and the factors that influence it, but doctors still cannot offer personalised treatments. This is because it has been difficult to understand what makes psoriasis more or less severe, why people respond differently to treatment, or why some people develop related diseases. To help address this, we collected skin and blood samples and personal information from people with severe psoriasis across the United Kingdom. Using computer-based methods, we found shared biological processes that link the disease with obesity and help predict its severity. Rider, Grantham, Smith, Watson et al. integrate multiomic data from patients with psoriasis using dimensionality reduction and machine learning techniques. This approach identifies biological relationships between genetic background, clinical features and disease severity, providing insight into disease variability across individuals.

Natural language and visualization are being increasingly deployed together for supporting data analysis in different ways, from multimodal interaction to enriched data summaries and insights. Yet, researchers still lack systematic knowledge on how viewers verbalize their interpretations of visualizations, and how they interpret verbalizations of visualizations in such contexts. We describe two studies aimed at identifying characteristics of data and charts that are relevant in such tasks. The first study asks participants to verbalize what they see in scatterplots that depict various levels of correlations. The second study then asks participants to choose visualizations that match a given verbal description of correlation. We extract key concepts from responses, organize them in a taxonomy and analyze the categorized responses. We observe that participants use a wide range of vocabulary across all scatterplots, but particular concepts are preferred for higher levels of correlation. A comparison between the studies reveals the ambiguity of some of the concepts. We discuss how the results could inform the design of multimodal representations aligned with the data and analytical tasks, and present a research roadmap to deepen the understanding about visualizations and natural language.

Electronic healthcare records (EHR) contain a huge wealth of data that can support the prediction of clinical outcomes. EHR data is often stored and analysed using clinical codes (ICD10, SNOMED), however these can differ across registries and healthcare providers. Integrating data across systems involves mapping between different clinical ontologies requiring domain expertise, and at times resulting in data loss. To overcome this, code-agnostic models have been proposed. We assess the effectiveness of a code-agnostic representation approach on the task of long-term microvascular complication prediction for individuals living with Type 2 Diabetes. Our method encodes individual EHRs as text using fine-tuned, pretrained clinical language models. Leveraging large-scale EHR data from the UK, we employ a multi-label approach to simultaneously predict the risk of microvascular complications across 1-, 5-, and 10-year windows. We demonstrate that a code-agnostic approach outperforms a code-based model and illustrate that performance is better with longer prediction windows but is biased to the first occurring complication. Overall, we highlight that context length is vitally important for model performance. This study highlights the possibility of including data from across different clinical ontologies and is a starting point for generalisable clinical models.

Developing artificial intelligence (AI) tools for healthcare is a multiple disciplinary effort, bringing data scientists, clinicians, patients and other disciplines together. In this paper, we explore the AI development workflow and how participants navigate the challenges and tensions of sharing and generating knowledge across disciplines. Through an inductive thematic analysis of 13 semi-structured interviews with participants in a large research consortia, our findings suggest that multiple disciplinarity heavily impacts work practices. Participants faced challenges to learn the languages of other disciplines and needed to adapt the tools used for sharing and communicating with their audience, particularly those from a clinical or patient perspective. Large health datasets also posed certain restrictions on work practices. We identified meetings as a key platform for facilitating exchanges between disciplines and allowing for the blending and creation of knowledge. Finally, we discuss design implications for data science and collaborative tools, and recommendations for future research.

Background: Over the past three decades there have been numerous molecular biology developments that have led to an explosion in the number of gene expression studies being performed. Many of these gene expression studies publish their data to the public database GEO, making them freely available. By analysing gene expression datasets, researchers can identify genes that are differentially expressed between two groups. This can provide insights that lead to the development of new tests and treatments for diseases. Despite the wide availability of gene expression datasets, analysing them is difficult for several reasons. These reasons include the fact that most methods for performing gene expression analysis require programming proficiency. Results: We developed the GEOexplorer software package to overcome several of the difficulties in performing gene expression analysis. GEOexplorer was therefore developed as a web application, that can perform interactive and reproducible microarray gene expression analysis, while producing a wealth of interactive visualisations to facilitate result exploration. GEOexplorer is implemented in R using the Shiny framework and is fully integrated with the existing core structures of the Bioconductor project. Users can perform the essential steps of exploratory data analysis and differential gene expression analysis intuitively and generate a broad spectrum of publication ready outputs. Conclusion: GEOexplorer is distributed as an R package in the Bioconductor project (http://bioconductor.org/packages/GEOexplorer/). GEOexplorer provides a solution for performing interactive and reproducible analyses of microarray gene expression data, empowering life scientists to perform exploratory data analysis and differential gene expression analysis on GEO microarray datasets. Competing Interest Statement The authors have declared no competing interest.

Despite increased understanding of psoriasis pathogenesis, molecular classification of clinical phenotypes and disease severity is poorly defined. Knowledge gaps include whether molecular endotypes of psoriasis underlie distinct clinical phenotypes and the positive and negative molecular regulators of disease severity across tissue compartments. We performed comprehensive RNA-sequencing of skin and blood (n=718) from prospectively-recruited, deeply-phenotyped discovery and replication cohorts of 146 subjects with moderate-to-severe psoriasis initiating TNF-inhibitor (adalimumab) or IL-12/23-inhibitor (ustekinumab) therapy. Using two complementary methods for dimensionality reduction, we defined distinct but interconnected co-expression modules and factors within skin and blood that were significantly associated with disease phenotypes and disease severity, as measured by Psoriasis Area Severity Index (PASI). We identified a 14-gene signature negatively associated with BMI in nonlesional skin and disease severity in lesional skin, respectively. Genotype integration revealed that HLA-DQA1*01 and HLA-DRB1*15 genotypes were positively associated with baseline disease severity. Using Gaussian process regression followed by SHAP (SHapley Additive exPlanations), we defined two core drug independent and disease severity-associated gene modules in lesional skin - one positive, one negative - and a lesional 9-gene signature predictive of disease severity. Disease severity signatures in blood were only seen following adalimumab exposure, suggesting greater systemic impact of adalimumab compared to ustekinumab, in line with its side effect profile. In contrast, a gene signature in blood linked to HLA-C*06:02 status was independent of disease severity or drug. These findings delineate gene-environmental and genetic effects on the psoriasis transcriptome linked to disease severity. Psoriasis is a common and debilitating skin disease, linked to multiple other inflammatory conditions. A lot is known about the mechanism of psoriasis and its inherited and external influences. Despite this, doctors cannot yet offer personalised treatments as it has been difficult to discover whether biological pathways are associated with disease severity, response to treatment or a person’s likelihood of having other linked diseases. To help address this, we collected skin and blood samples and the personal characteristics of a group of people with severe psoriasis across the United Kingdom. Using computer-based methods, we discovered common biological processes underlying different psoriasis types, including genes that connect psoriasis severity with obesity, and another set of genes that help predict disease severity.